I tumori gliali. La nostra esperienza radioterapica

Translated title of the contribution: Malignant gliomas. Our radiotherapy experience

M. Arcicasa, M. Roncadin, R. Bortolus, G. Tortorici, E. Covezzi, E. Bidoli, G. Bassignano, P. Passadore, B. Lucci

Research output: Contribution to journalArticle

Abstract

From 1978 to 1992, 135 consecutive patients with high grade glioma were treated at the Radiotherapy Department of Pordenone General Hospital. The patients were divided into 4 group (on the basis of the time of diagnosis): Group I, surgery if feasible followed by radiotherapy to the brain to a total dose of 34 Gy in 4 fractions, VCR (2 mg i.v.) and BCNU (80 mg/m2i.v.) repeated every 6 weeks; Group II, surgery if feasible and radiotherapy with the same schedule as Group I plus VP16 (75 mg/m2 i.v.) every 3 weeks and BCNU(50 mg/m2 i.v.) every 6 weeks; Group III, surgery if feasible and radiotherapy given to the brain to a total dose of 60 Gy in 30 fractions over 6 weeks plus VCR (2 mg i.v.), BCNU (50 mg/m2) and CDDP (15 mg/m2 i.v.) every 6 weeks; Group IV, after surgery when feasible, radiotherapy with the same schedule as Group III plus BCNU (40 mg/m2) and CDDP (40 mg/m2) given for 3 days in continues, simultaneous infusion, every 6 weeks. On April 30, 1996, in Group I, 28 patients had stable disease (SD) and 2 patients had disease progression. The median survival time was 9 months (range 1-18). In Group II there were 22 SDs. The median survival time was 6 months (range 2-16). In Group III there were 29 SDs and 14 partial remissions. The median survival time was 13 months (range 3-112,5+). In Group IV there were 34 SDs and 6 partial remissions. The median survival time was 13,5 months (range 3-92+). In general, the group of patients treated with radical or subtotal surgery and the patients included in neurological classes I and II, with performance status ≤ 70, and younger than 45 years had a longer survival. In our experience, the patients with a diagnosis of grade III and IV glioma included in the Groups III and IV had a longer survival than those in Groups I and II. None of the patients experienced severe toxicity from the treatment.

Translated title of the contributionMalignant gliomas. Our radiotherapy experience
Original languageItalian
Pages (from-to)23-30
Number of pages8
JournalRivista di Neurobiologia
Volume43
Issue number1
Publication statusPublished - 1997

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Malignant gliomas. Our radiotherapy experience'. Together they form a unique fingerprint.

  • Cite this

    Arcicasa, M., Roncadin, M., Bortolus, R., Tortorici, G., Covezzi, E., Bidoli, E., Bassignano, G., Passadore, P., & Lucci, B. (1997). I tumori gliali. La nostra esperienza radioterapica. Rivista di Neurobiologia, 43(1), 23-30.